Last reviewed · How we verify
Immunological and tumour characterization
At a glance
| Generic name | Immunological and tumour characterization |
|---|---|
| Sponsor | Centre Leon Berard |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer (NA)
- Study of Biomarkers in Gynecological Cancers (NA)
- Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy
- Clinico-immunological Characterization and Immune Tolerance Breakdown in CV2-autoimmunity
- ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma (PHASE2)
- Characterization of Biophysical and Mechanical Parameters on Skin of Breast Cancer Patients
- Immunotolerance in Endometrial Cancer and at the Maternal-fetal Interface: Immunological Profiling of the Tumor Microenvironment in Risk Stratification of Recurrence
- Molecular Characterizazion and Biological Samples Centralisation of Patients Affected by Oncoematolofic Pathology (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: